Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma

ofile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma Review (1097) Total Article Views Authors: Walsh GM Published Date January 2013 Volume 2013:7 Pages 7 - 11 DOI: http://dx.doi.org/10.2147/BTT.S30133 Received: 23 November 2012 Accepted: 14 December 2012 Published: 09 January 2013 Garry M Walsh Division of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK Abstract: Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, and persistence in the tissues. Reslizumab (Cinquil ) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma. This review will consider the current status of the clinical development of reslizumab for asthma and in other inflammatory diseases with a marked eosinophilic component.